Remove 2024 Remove CMS Remove Technology
article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

Getty Images milla1cf Wed, 03/13/2024 - 16:49 March 13, 2024 — BioCardia, Inc. , Getty Images milla1cf Wed, 03/13/2024 - 16:49 March 13, 2024 — BioCardia, Inc. , We are pleased that CMS has provided coverage support for the confirmatory CardiAMP Heart Failure II study.” said Peter Altman , PhD.,

CMS 111
article thumbnail

CMS Updates Medicare Coverage for AI-Coronary Plaque Analysis

DAIC

tim.hodson Wed, 10/16/2024 - 12:36 Oct. 15 , 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). The four contractors for the U.S. The LCDs have a future effective date of Nov.

CMS 52
article thumbnail

HeartFlow Announces New Reimbursement Code and Increased Payment for FFRCT

DAIC

milla1cf Tue, 01/23/2024 - 13:44 January 23, 2024 — HeartFlow, Inc. , a leader in non-invasive artificial intelligence (AI) precision coronary solutions, announced FFRCT was transitioned to a Category I Current Procedural Terminology (CPT) code beginning January 1, 2024.

article thumbnail

HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage

DAIC

milla1cf Tue, 06/04/2024 - 20:54 June 4, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for future expanded patient access to their Plaque Analysis product.

Medicare 104
article thumbnail

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

DAIC

mtaschetta-millane Mon, 07/29/2024 - 09:02 July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth.

article thumbnail

CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

DAIC

tim.hodson Fri, 11/08/2024 - 09:57 Nov. 1, 2024 — Recor Medical, Inc. Centers for Medicare & Medicaid Services (CMS) have granted the company’s Paradise Ultrasound Renal Denervation system a Transitional Pass-through (TPT) payment. and its parent company, Otsuka Medical Devices Co. recently announced U.S.

CMS 40
article thumbnail

The Evolving Computed Tomography Market

DAIC

Computed Tomography (CT) continues to be a rapidly evolving technology with many new advancements, as displayed and discussed at the Radiological Society of North America109th Scientific Assembly and Annual Meeting (RSNA23). As a whole, the computed tomography market size in the US in 2024 is estimated to be $2.38